CoChat

FXR an emerging therapeutic target for the treatment of atherosclerosis

Open access
Mencarelli, Andrea, Fiorucci, Stefano · 2010 · Journal of Cellular and Molecular Medicine
Cited by 91

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Abstract

• Introduction • Molecular biology of FXR • Is there a role for FXR in atherosclerosis? - Role of FXR in metabolism - Cholesterol metabolism - Bile synthesis - Cholesterol absorption - Liver cholesterol metabolism - A synthesis - B LDL-cholesterol - C HDL-cholesterol - Triglycerides metabolism - Glucose metabolism - Hepatic gluconeogenesis - Insulin sensitivity - Role of FXR effects in vessel wall - Endothelial cells - Vascular smooth muscle cells - Modulation of macrophages-inflammatory response • Lessons from FXR null mice and experimental models of atherosclerosis • Conclusion Atherosclerosis is the leading cause of illness and death. Therapeutic strategies aimed at reducing cholesterol plasma levels have shown efficacy in either reducing progression of atherosclerotic plaques and atherosclerosis-related mortality. The farnesoid-X-receptor (FXR) is a member of metabolic nuclear receptors (NRs) superfamily activated by bile acids. In entero-hepatic tissues, FXR functions as a bile acid sensor regulating bile acid synthesis, detoxification and excretion. In the liver FXR induces the expression of an atypical NR, the small heterodimer partner, which subsequently inhibits the activity of hepatocyte nuclear factor 4α repressing the transcription of cholesterol 7a-hydroxylase, the critical regulatory gene in bile acid synthesis. In the intestine FXR induces the release of fibroblast growth factor 15 (FGF15) (or FGF19 in human), which activates hepatic FGF receptor 4 (FGFR4) signalling to inhibit bile acid synthesis. In rodents, FXR activation decreases bile acid synthesis and lipogenesis and increases lipoprotein clearance, and regulates glucose homeostasis by reducing liver gluconeogenesis. FXR exerts counter-regulatory effects on macrophages, vascular smooth muscle cells and endothelial cells. FXR deficiency in mice results in a pro-atherogenetic lipoproteins profile and insulin resistance but FXR−/– mice fail to develop any detectable plaques on high-fat diet. Synthetic FXR agonists protect against development of aortic plaques formation in murine models characterized by pro-atherogenetic lipoprotein profile and accelerated atherosclerosis, but reduce HDL levels. Because human and mouse lipoprotein metabolism is modulated by different regulatory pathways the potential drawbacks of FXR ligands on HDL and bile acid synthesis need to addressed in relevant clinical settings.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1582-4934.2009.00997.x

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 91

Metadata

Authors
Mencarelli, A., & Fiorucci, S.
Venue
Journal of Cellular and Molecular Medicine
Publisher
Wiley
Published
2010-01
Volume
14
Issue
1-2
Pages
79-92
ISSN
  • 1582-1838 (ISSN-L)
  • 1582-4934
OpenAlex
W1977493036
Cited by
91
References
18
FWCI
4.92
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: FXR an emerging therapeutic target for the treatment of atherosclerosis. https://app.cochat.ai/papers/10.1111/j.1582-4934.2009.00997.x
The paper
Mencarelli, A., & Fiorucci, S. (2010). FXR an emerging therapeutic target for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2009.00997.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.